Silver Oak Securities’s SAB Biotherapeutics SABS Stock Holding History

Silver Oak Securities’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,188	Closed	-$29.9K	–	722
2025 Q1	$29.9K	Buy	+20,188	New	+$46.3K	﹤0.01%	639
2024 Q1	–	Sell	-5,189	Closed	-$35.7K	–	537
2023 Q4	$35.7K	Buy	+5,189	New	+$43.5K	﹤0.01%	487
2023 Q3	–	Sell	-5,189	Closed	-$43K	–	491
2023 Q2	$43K	Hold	5,189	–	–	0.01%	421
2023 Q1	$23K	Sell	5,189 -5	-0.1%	-$32	﹤0.01%	396
2022 Q4	$31K	Buy	+5,194	New	+$47.5K	0.01%	302
2022 Q3	–	Sell	-5,194	Closed	-$64K	–	496
2022 Q2	$64K	Buy	+5,194	New	+$109K	0.01%	277

Other funds holding SABS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Kovitz Investment Group Partners Chicago, Illinois $4.31B AUM 20.41% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Silver Oak Securities's SABS Position: Q2 2025 in Review

Silver Oak Securities sold out of SAB Biotherapeutics (SABS) in Q2 2025, closing a stake of 20,188 shares — an estimated $29.9K sold.

Silver Oak Securities first reported a position in SABS in Q2 2022 and held it in 6 quarters. The position peaked at $64K in Q2 2022. 25 funds tracked by Wall St. Rank hold SABS as of Q2 2025.

Silver Oak Securities reported no remaining SAB Biotherapeutics position as of Q2 2025 after selling out during the quarter.
Silver Oak Securities sold 20,188 SAB Biotherapeutics shares in Q2 2025, an estimated $29.9K.
Silver Oak Securities first reported a position in SAB Biotherapeutics in Q2 2022 and held it in 6 quarters.
Silver Oak Securities's SAB Biotherapeutics position peaked at $64K in Q2 2022.
25 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2025.

Based on Silver Oak Securities's 13F filing for Q2 2025, filed 11 Jul 2025.